Latest News
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceutical company PharmaMar, has secured MHRA approval f...
Pfizer's tilrekimig shows significant skin clearance in Phase 2 atopic dermatitis study
1 October 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday reported positive Phase 2 results for investigational tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis, with the study meeting its primary end...
Sanofi and Regeneron expand antibody alliance with four next-generation immunology programmes
1 October 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) said on Thursday that they have expanded their more than 20-year antibody collaboration ...
AFYREN ingredient enables global launch of natural propionic acid skincare product
1 October 2026 - Greentech company AFYREN (Euronext Paris:ALAFY) said on Thursday that it its 100% bio-based, COSMOS-certified propionic acid has enabled the global launch of Esse Barrier Rescue, developed with South Africa-based microbiome skincare ...
CVS Health declares unchanged quarterly dividend
1 October 2026 - US healthcare company CVS Health (NYSE:CVS) announced on Wednesday that its board of directors has approved a quarterly dividend of USD0.665 per share on its common stock.This amount is unchanged from the previous quarterly dividend....